


## AMG-548

<b>Cat. No.:</b>	HY-108642		
<b>CAS No.:</b>	864249-60-5		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>27</sub> N <sub>5</sub> O		
<b>Molecular Weight:</b>	461.56		
<b>Target:</b>	p38 MAPK; Casein Kinase		
<b>Pathway:</b>	MAPK/ERK Pathway; Cell Cycle/DNA Damage; Stem Cell/Wnt		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



## BIOLOGICAL ACTIVITY

<b>Description</b>	AMG-548, an orally active and selective p38 $\alpha$ inhibitor ( $K_i=0.5$ nM), shows slightly selective over p38 $\beta$ ( $K_i=36$ nM) and >1000 fold selective against p38 $\gamma$ and p38 $\delta$ . AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated TNF $\alpha$ ( $IC_{50}=3$ nM) <sup>[1]</sup> . AMG-548 inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms $\delta$ and $\epsilon$ <sup>[2]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	p38 $\alpha$ 0.5 nM (Ki)	p38 $\beta$ 3.6 nM (Ki)	p38 $\delta$ 2600 nM (Ki)	p38 $\gamma$ 4100 nM (Ki)
	dog p38 $\alpha$ 5.0 nM (Ki)	JNK1 11480 nM (Ki)	JNK2 39 nM (Ki)	JNK3 61 nM (Ki)
	CK1			
<b>In Vitro</b>	AMG-548 shows >1000 fold selective against p38 $\gamma$ ( $K_i=2600$ nM) and p38 $\delta$ ( $k_i=4100$ nM). AMG-548 has a modest selectivity against JNK2 ( $k_i=39$ nM) and JNK3 ( $k_i=61$ nM). AMG-548 is also extremely potent in the inhibition of whole blood LPS stimulated TNF $\alpha$ ( $IC_{50}=3$ nM) and IL1 $\beta$ ( $IC_{50}=7$ nM) as well as TNF $\alpha$ induced IL-8 ( $IC_{50}=0.7$ nM) and IL-1 $\beta$ induced IL-6 ( $IC_{50}$ <sub>50</sub> =1.3 nM) in human whole blood <sup>[1]</sup> . AMG-548 (10 $\mu$ M) inhibits the hDvl2 shift <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
<b>In Vivo</b>	AMG-548 has rat F of 62% and dog F of 47%. The $t_{1/2}$ is 4.6 hours in rats and 7.3 hours in dogs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## REFERENCES

- [1]. Lee MR, et al. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38 $\alpha$  protein. *Curr Med Chem.* 2005;12(25):2979-94.
- [2]. Verkaar F, et al. Inhibition of Wnt/ $\beta$ -catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase I $\delta/\epsilon$ . *Chem Biol.* 2011 Apr 22;18(4):485-94.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA